title: Helicobacter pylori eradication is superior to ulcer healing with or without maintenance therapy to prevent further ulcer haemorrhage.
abstract: BACKGROUND
  Helicobacter pylori eradication decreases ulcer recurrence and should prevent recurrent ulcer haemorrhage.
  
  
  OBJECTIVE
  By meta-analysis, to compare treatment of H. pylori infection with other approaches to prevent recurrent ulcer haemorrhage and, by cost minimization analysis, to determine the least costly strategy.
  
  
  METHODS
  We searched for randomized, controlled trials comparing treatment of H. pylori infection with ulcer healing alone or with maintenance therapy in preventing recurrent ulcer haemorrhage. We calculated the relative and absolute risk reductions and numbers needed to treat.
  
  
  RESULTS
  Treatment of H. pylori infection decreased recurrent bleeding by 17% (numbers needed to treat=6) compared with ulcer healing treatment alone. Compared with ulcer healing treatment followed by maintenance therapy, recurrent bleeding was decreased by 4% (numbers needed to treat=25). Decision model-based cost minimization analysis demonstrated that treatment of H. pylori infection was the least costly strategy unless the incidence of complicated recurrences after treatment was over 6%, or the cost of confirming eradication was over $741.
  
  
  CONCLUSIONS
  Treatment of H. pylori infection is superior to ulcer healing treatment with or without maintenance therapy in preventing recurrent ulcer haemorrhage. All patients with ulcer bleeding should be tested for H. pylori infection and appropriately treated if positive.
authors.affiliation: Division of Digestive Diseases, Department of Medicine, University of Arkansas for Medical Sciences, Little Rock, AR, USA.
authors.forename: V K
authors.initials: VK
authors.lastname: Sharma
authors.forename: A V
authors.initials: AV
authors.lastname: Sahai
authors.forename: F A
authors.initials: FA
authors.lastname: Corder
authors.forename: C W
authors.initials: CW
authors.lastname: Howden
mesh_terms: D000900:Anti-Bacterial Agents / Q000627:therapeutic use; D000897:Anti-Ulcer Agents / Q000627:therapeutic use; D001729:Bismuth / Q000627:therapeutic use; D004359:Drug Therapy, Combination; D016481:Helicobacter Infections / Q000188:drug therapy* / Q000191:economics / Q000382:microbiology; D016480:Helicobacter pylori / Q000187:drug effects*; D006801:Humans; D016239:MEDLINE; D008795:Metronidazole / Q000627:therapeutic use; D009853:Omeprazole / Q000627:therapeutic use; D009942:Organometallic Compounds / Q000627:therapeutic use; D010438:Peptic Ulcer Hemorrhage / Q000191:economics / Q000517:prevention & control*; D016032:Randomized Controlled Trials as Topic; D011899:Ranitidine / Q000627:therapeutic use; D012008:Recurrence; D012307:Risk Factors; D012459:Salicylates / Q000627:therapeutic use; D012680:Sensitivity and Specificity
chemical_list: D000900:Anti-Bacterial Agents; D000897:Anti-Ulcer Agents; D009942:Organometallic Compounds; D012459:Salicylates; D008795:Metronidazole; C015715:bismuth subsalicylate; D011899:Ranitidine; D009853:Omeprazole; D001729:Bismuth